Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
David I. Cantor, Harish R. Cheruku, Jack Westacott, Joo-Shik Shin, Abidali Mohamedali & Seong Boem Ahn. (2020) Proteomic investigations into resistance in colorectal cancer. Expert Review of Proteomics 17:1, pages 49-65.
Read now
Read now
Articles from other publishers (20)
Kuei-Yen Tsai, Yu-Jia Chang, Chien-Yu Huang, G. M. Shazzad Hossain Prince, Hsin-An Chen, Precious Takondwa Makondi, Ying-Rou Shen & Po-Li Wei. (2023) Novel heavily fucosylated glycans as a promising therapeutic target in colorectal cancer. Journal of Translational Medicine 21:1.
Crossref
Crossref
Sara Cherradi, Véronique Garambois, Johanna Marines, Augusto Faria Andrade, Alexandra Fauvre, Olivia Morand, Manon Fargal, Ferial Mancouri, Adeline Ayrolles-Torro, Nadia Vezzo-Vié, Marta Jarlier, Gerald Loussaint, Steve Huvelle, Nicolas Joubert, Thibault Mazard, Céline Gongora, Philippe Pourquier, Florence Boissière-Michot & Maguy Del Rio. (2023) Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells. Cell & Bioscience 13:1.
Crossref
Crossref
Flaviana Marzano, Mariano Francesco Caratozzolo, Graziano Pesole, Elisabetta Sbisà & Apollonia Tullo. (2021) TRIM Proteins in Colorectal Cancer: TRIM8 as a Promising Therapeutic Target in Chemo Resistance. Biomedicines 9:3, pages 241.
Crossref
Crossref
Ângela Fernandes, Ana M. Dias, Mariana C. Silva, Joana Gaifem, Catarina M. Azevedo, Iago Carballo & Salomé S. Pinho. 2021. Comprehensive Glycoscience. Comprehensive Glycoscience
444
470
.
Sona Vodenkova, Tomas Buchler, Klara Cervena, Veronika Veskrnova, Pavel Vodicka & Veronika Vymetalkova. (2020) 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacology & Therapeutics 206, pages 107447.
Crossref
Crossref
Kevin Van der Jeught, Han-Chen Xu, Yu-Jing Li, Xiong-Bin Lu & Guang Ji. (2018) Drug resistance and new therapies in colorectal cancer. World Journal of Gastroenterology 24:34, pages 3834-3848.
Crossref
Crossref
Ninon Very, Tony Lefebvre & Ikram El Yazidi-Belkoura. (2017) Drug resistance related to aberrant glycosylation in colorectal cancer. Oncotarget 9:1, pages 1380-1402.
Crossref
Crossref
Jia Che, Lun Pan, Xiangling Yang, Zhiting Liu, Lanlan Huang, Chuangyu Wen, Aihua Lin & Huanliang Liu. (2017) Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5‑fluorouracil‑based chemotherapy: A meta‑analysis. Molecular and Clinical Oncology.
Crossref
Crossref
William A. Hammond, Abhisek Swaika & Kabir Mody. (2015) Pharmacologic resistance in colorectal cancer: a review. Therapeutic Advances in Medical Oncology 8:1, pages 57-84.
Crossref
Crossref
Tze-Kiong Er, Luis Bujanda, Maximiliano Rodrigo & Marta Herreros-Villanueva. (2015) Pharmacogenomic biomarkers for colorectal cancer treatment. Cancer Treatment Communications 4, pages 121-127.
Crossref
Crossref
Elinor Bexe Lindskog, Kristoffer Derwinger, Bengt Gustavsson, Peter Falk & Yvonne Wettergren. (2014) Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer. BMC Clinical Pathology 14:1.
Crossref
Crossref
Beatrice Mohelnikova-Duchonova. (2014) FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy. World Journal of Gastroenterology 20:30, pages 10316.
Crossref
Crossref
Mariusz Panczyk. (2014) Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World Journal of Gastroenterology 20:29, pages 9775.
Crossref
Crossref
Francesco Crea, Stefania Nobili, Elisa Paolicchi, Gabriele Perrone, Cristina Napoli, Ida Landini, Romano Danesi & Enrico Mini. (2011) Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies. Drug Resistance Updates 14:6, pages 280-296.
Crossref
Crossref
A. Fariña-Sarasqueta, M. J. E. M. Gosens, E. Moerland, I. van Lijnschoten, V. E. P. P. Lemmens, G. D. Slooter, H. J. T. Rutten & Adriaan J. C. van den Brule. (2011) TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients. Cellular Oncology 34:4, pages 327-335.
Crossref
Crossref
Mario Scartozzi, Elena Maccaroni, Riccardo Giampieri, Mirco Pistelli, Alessandro Bittoni, Michela Del Prete, Rossana Berardi & Stefano Cascinu. (2011) 5-fluorouracil pharmacogenomics: still rocking after all these years?. Pharmacogenomics 12:2, pages 251-265.
Crossref
Crossref
Arantza Fariña-Sarasqueta, Gesina van Lijnschoten, Harm J. T. Rutten & Adriaan J. C. van den Brule. (2010) Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study. Cancer Chemotherapy and Pharmacology 66:6, pages 1167-1171.
Crossref
Crossref
Miriam Koopman, Sabine Venderbosch, Iris D. Nagtegaal, Johan H. van Krieken & Cornelis J. Punt. (2009) A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?. European Journal of Cancer 45:11, pages 1935-1949.
Crossref
Crossref
Miriam Koopman, Sabine Venderbosch, Harm van Tinteren, Marjolijn J. Ligtenberg, Iris Nagtegaal, Johan H. Van Krieken & Cornelis J. Punt. (2009) Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. European Journal of Cancer 45:11, pages 1999-2006.
Crossref
Crossref
Li‐Xin Qiu, Qi‐Yun Tang, Jian‐Ling Bai, Xiao‐Ping Qian, Ru‐Tian Li, Bao‐Rui Liu & Ming‐Hua Zheng. (2008) Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine‐based chemotherapy: Evidence from 24 studies. International Journal of Cancer 123:10, pages 2384-2389.
Crossref
Crossref